Latest news

• bluebird bio lodges counterclaim against Spark Therapeutics

  Specifically, the complaint accuses bluebird bio of infringing on and diluting Spark Therapeutics’ trademark, relating to bluebird bio’s educational and informational campaign about sickle cell disease ‘Be the Spark’ which ... The biotech company

• Roche moving closer to approval of Spark takeover; report

  neparvovec) for a rare inherited retinal disease – as well as four other candidates in clinical trials headed by haemophilia A therapy SPK-8011.

• Roche buys gene therapy specialist Spark for $4.3bn

  The $114.50 per share deal will give the Swiss pharma giant rights the approved therapy Luxturna (voretigene neparvovec) for a rare inherited retinal disease, as well as four candidates in ... Also in Spark’s pipeline is SPK-7001 for choroideremia in

• J&J bolsters gene therapy unit with $100m MeiraGTx deal

  The companies will also work together on new targets for other inherited retinal diseases and on adeno-associated virus (AAV) manufacturing technology. ... The US market developed a little later, with Spark Therapeutics’ Luxturna (voretigene neparvovec

• Freeline raises £88m to accelerate haemophilia gene therapy

  additional testing of its lead haemophilia B gene therapy, and take another for Fabry disease into the clinic. ... This adds to Freeline and its focus on chronic systemic disease, Nightstar ( specialising in inherited retinal diseases), and Gyroscope,